3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Lung Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Hematologic Neoplasms
2
Solid Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma
1
Lung Diseases
1
Genomic Instability
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
ALK+ Advanced NSCLC
1
Interventions
Carboplatin
7
Paclitaxel
4
Cisplatin
4
pembrolizumab
3
Pemetrexed
3
zipalertinib
2
selpercatinib
2
durvalumab
2
Nivolumab
2
Blood Specimen Collection
2
zimberelimab
1
taletrectinib
1
sotorasib
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
alectinib
1
Tomography, Emission-Computed, Single-Photon
1
Toll-Like Receptor 1
1
Telescopes
1
Surveys and Questionnaires
1
Radiosurgery
1
One-Lung Ventilation
1
Omacor
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Health Records, Personal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
alectinib
×
1 year
×
Clear all
NCT06765109
2026-06-02
ALKAZAR
Nuvalent Inc.
Phase 3
Recruiting
450 enrolled